The bioluminescence resonance energy transfer (BRET) technique has become extremely popular for studying proteinprotein interactions in living cells and real time. Of particular interest is the ability to monitor interactions between G protein-coupled receptors, such as the thyrotropin-releasing hormone receptor (TRHR), and proteins critical for regulating their function, such as β-arrestin. Using TRHR/β-arrestin interactions, we have demonstrated improvements to all 3 generations of BRET (BRET 1 , BRET 2 , and eBRET) by using the novel forms of luciferase, Rluc2 and Rluc8, developed by the Gambhir laboratory. Furthermore, for the 1st time it was possible to use the BRET2 system to detect ligand-induced G protein-coupled receptor/β-arrestin interactions over prolonged periods (on the scale of hours rather than seconds) with a very stable signal. As demonstrated by our Z′-factor data, these luciferases increase the sensitivity of BRET to such an extent that they substantially increase the potential applicability of this technology for effective drug discovery high-throughput screening. (Journal of Biomolecular Screening 2008:888-898) 
INTRODUCTION
B IOLUMINESCENCE RESONANCE ENERGY TRANSFER (BRET) has been used extensively to monitor protein-protein interactions in living cells and real time. [1] [2] [3] In particular, it has been used for studying G protein-coupled receptor (GPCR) interactions with both membrane and cytosolic proteins. 2, [4] [5] [6] The BRET procedure involves coexpression of genetically fused proteins that link proteins of interest to a bioluminescent donor enzyme, a variant of Renilla luciferase (Rluc), or an acceptor fluorophore, a variant of green fluorescent protein (GFP). If the Rluc and GFP variants are less than 10 nm apart, 7 energy resulting from the oxidation of the coelenterazine substrate by the Rluc will transfer to the GFP variant, which in turn fluoresces at a longer wavelength. Energy transfer implies that these molecules are in close proximity, and therefore, the proteins of interest fused to the donor and acceptor interact directly or as part of a complex. 1 The originally described BRET technology, now referred to as BRET 1 , utilizes oxidation of the luciferase substrate coelenterazine h (benzyl-coelenterazine) resulting in light emission with a peak at ~480 nm. Using the current BRET 1 system it is possible to detect BRET signals for up to about 1 h. 2, 8 To prolong the detection period, a long-acting form of coelenterazine h was developed called EnduRen, and subsequently the extended BRET (eBRET) method was established. 8 EnduRen is a protected form of coelenterazine h with identical spectral properties; however, in contrast to coelenterazine h its signal can last for several hours. 8 Using BRET 1 or eBRET, overlap between donor and acceptor emission spectra is substantial, resulting in a relatively high background signal that needs to be taken into account. 5 In contrast, the BRET 2 system uses a coelenterazine analogue called DeepBlueC (bisdeoxycoelenterazine, coelenterazine-400a, di-dehydro coelenterazine), producing a ~400-nm emission peak upon Rluc-mediated oxidation and utilizing GFP10 or GFP 2 as acceptor. The advantage of BRET 2 is the increased separation of donor and acceptor emission spectra, which provides greater signal resolution. However, DeepBlueC suffers from rapid signal decay and low quantum yield (>100-fold lower than coelenterazine h). 2, 9 Thus, the detection period of the BRET 2 signal with Rluc as donor lasts for a matter of seconds and substrate injection is generally required to enable signal detection. 2 These disadvantages have substantial practical implications when using BRET 2 for detecting protein-protein interactions.
We have compared the performance of 2 novel luminophores, Rluc2 and Rluc8, 10, 11 alongside standard Renilla luciferases with and without codon-humanization (hRluc and Rluc, respectively) in BRET 1 , BRET 2 , and eBRET assays. It is clearly advantageous to be able to detect weak and/or transient protein-protein interactions at physiologically relevant protein expression levels. Therefore, improvements to BRET signal intensity, stability, and/or duration are likely to substantially increase the effectiveness of BRET technologies to achieve this aim, particularly with respect to BRET 2 . Loening et al. 10 constructed specific hRluc mutants with the aim of further improving the enzyme as a bioluminescent tag. These novel hRluc variants, Rluc2 (C124A/M185V) and Rluc8 (A55T/C124A/ S130A/K136R/A143M/M185V/M253L/S287L), exhibit significantly improved properties compared to nonmutated luciferases, including increased light output when used with coelenterazine analogues and better stability in serum at 37 °C.
We have observed agonist-induced interactions between β-arrestin 2 and thyrotropin-releasing hormone receptor (TRHR) in live cells. TRH, acting via the TRHR, plays a critical role in controlling thyroid-stimulating hormone and prolactin production from the anterior pituitary gland, 12, 13 as well as exhibiting a range of extrapituitary actions. 13 β-Arrestins have an important function in TRHR signaling and regulation. 13 Following agonist binding, the active receptor is phosphorylated by GPCR kinases (GRKs) that increase GPCR binding affinity for β-arrestins. 14, 15 β-Arrestin interaction results in receptor desensitization with respect to G protein-mediated signaling and internalization into clathrin-coated pits, thereby preventing further agonist binding and stimulation. β-Arrestins have also been shown to act as adapter molecules capable of triggering additional signaling events, via mitogen-activated protein kinase (MAPK) pathways, for example, leading to cytoplasmic localization and activation of signaling components. 15, 16 Therefore, GPCR/β-arrestin interactions dictate the initiation of temporally and spatially separable signaling events that are independent of and/or additional to G protein-mediated signaling. Indeed, GPCR agonist-activated signaling is believed to occur on a time scale well beyond that normally observed with G proteinmediated signalling, 17, 18 and the ability to monitor such interactions in real time is becoming increasingly important. 8, 17 For the 1st time, we were able to detect agonist-induced BRET 2 signals for over an hour in addition to observing more robust and consistent BRET 1 and eBRET signals. Furthermore, signals have been shown to be dependent upon agonist dose and cell number. These results open up exciting possibilities, not only to increase our ability to study protein-protein interactions at physiologically relevant expression levels, but also to effectively utilize the BRET technology for drug discovery high-throughput screening.
MATERIALS AND METHODS

Materials
TRH was from Bachem (Torrance, CA). TRHR/Rluc has been described previously. 12 hRluc cDNA was amplified from the phRL-SV40 vector (Promega, Madison, WI). Rluc2 and Rluc8 cDNAs were amplified from the constructs pcDNA3.1-RlucC124A/M185V and pcDNA3.1-Rluc8, respectively. These were kindly provided by Andreas Loening and Sanjiv Gambhir (Stanford University, Stanford, CA). 10 PCR products for hRluc, Rluc2, or Rluc8 coding regions were substituted in-frame into pcDNA3-TRHR/Rluc replacing the Rluc cDNA to generate TRHR/hRluc, TRHR/Rluc2, and TRHR/Rluc8.
The β-arrestin 2/Venus construct was prepared from pcC2-Venus kindly provided by Atsushi Miyawaki (RIKEN Brain Science Institute, Wako-city, Japan). A PCR product for the Venus coding sequence was substituted in-frame into pcDNA3β-arrestin 2/Rluc replacing the Rluc cDNA. The Venus coding sequence was amplified by PCR using the oligonucleotides 5′-TATTGGCGGCCGCATGGATCCACCATG-3′ introducing a NotI restriction site upstream of the Venus start codon and 5′-TATAGTTCTAGAGGCTCGAGAGGCCTTG-3′ introducing an XbaI restriction site after the Venus stop codon. The resulting PCR product was cleaved with NotI and XbaI, gel purified using the QIAEX kit (Qiagen), and cloned into the pcDNA3-βarrestin 2/Rluc vector cut with the same restriction enzymes, resulting in plasmid pcDNA3-β-arrestin 2/Venus.
The β-arrestin 2/GFP10 construct was prepared from the vector pcDNA3.1/GFP10 kindly provided by Michel Bouvier (Department of Biochemistry, Université de Montréal, Montréal, Quebec, Canada). A PCR product for the GFP10 coding sequence was substituted in-frame into pcDNA3-β-arrestin 2/Venus replacing the Venus cDNA. A 5′-primer was designed to incorporate a NotI restriction site upstream from the start codon (5′-TATTG-GCGGCCGCATCACATGGTGAGCAAGGGCGAG-3′) and a 3′-primer designed to incorporate a downstream XbaI restriction site (5′-TATAGTTCTAGATTACTTGTACAGCTCGTCCATG-3′). The resultant PCR product was then cut with NotI and XbaI, gel purified using the QIAEX kit (Qiagen), and cloned in-frame into pcDNA3-β-arrestin 2 prepared by digestion of pcDNA3-βarrestin 2/Venus with the same restriction enzymes. All construct sequences were confirmed by DNA sequencing at the Australian Genome Research Facility (AGRF), Brisbane.
Cell culture and transfection
HEK293 cells were maintained at 37 °C, 5% CO 2 in Complete Media (Dulbecco's Modified Eagle Medium containing 0.3 mg/ml glutamine, 100 IU/ml penicillin, and 100 μg/ml streptomycin; Gibco-BRL, Gaithersburg, MD) supplemented with 10% fetal calf serum (FCS; Gibco Life Technologies, Paisley, UK). Transient transfections were carried out 24 h after seeding using GeneJuice (Novagen) according to the manufacturer's instructions. The HEK293 cells detached easily upon addition of medium by pipette and thus were harvested without trypsin.
Measurement of total inositol phosphate production
HEK293 cells were seeded in 60-mm dishes at a density of 1 million cells/dish and transiently transfected the next day.
Twenty-four hours after transfection cells were split into 24-well plates, in inositol-free Complete Medium (MP Biomedicals, Irvine, CA) containing 1% dialyzed FCS. Six to 8 h later medium was replaced with inositol-free medium containing 1% dialyzed FCS and 1 μCi/ml [ 3 H]myo-inositol (Amersham Pharmacia Biotech, Uppsala, Sweden), followed by overnight incubation. Medium was removed and cells washed once with buffer A (1 mg/ml fatty acid-free BSA, 140 mM NaCl, 20 mM HEPES, 4 mM KCl, 8 mM D-glucose, 1 mM MgCl 2 , and 1 mM CaCl 2 ), and again with buffer A plus 10 mM LiCl before incubating at 37 °C for 50 min in buffer A containing 10 mM LiCl with or without 1 μM TRH. After incubation, the assay buffer was removed and replaced with 10 mM formic acid for 1 h at 4 °C. The acid was subsequently transferred to 5-ml tubes and the inositol phosphates bound to AG1-X8 anion-exchange resin (Bio-Rad Laboratories, Hercules, CA). Following washes with water and 60 mM ammonium formate/5 mM sodium tetraborate, inositol phosphates were eluted with 1 M ammonium formate/0.1 M formic acid; 1-ml samples were mixed with 4 ml of Optiphase HiSafe 2 scintillant (Wallac, Turku, Finland) and radioactivity measured using a 1209 Rackbeta liquid scintillation counter (Wallac). Total inositol phosphates were obtained by solubilizing cells in plates and inositol phosphate counts obtained from resin expressed relative to total inositol phosphate counts. All treatments were performed in triplicate.
Spectral analysis of luminescent proteins
HEK293 cells were seeded in 6-well plates at a density of 630,000 cells per well. Twenty-four hours after transfection, cells were harvested without trypsin in HEPES-buffered phenol red-free Complete Medium containing 5% FCS and added to a poly-L-lysine-coated white 96-well plate (Nunc brand). Subsequently, the plate was incubated at 37 °C, 5% CO 2 . Fortyeight hours after transfection, medium in the plate was replaced with medium containing 1 μM TRH (treated sample) or phosphate-buffered saline vehicle (PBS; untreated sample). After ~1 h, emission spectral scans were performed with 5 μM coelenterazine h or 10 μM DeepBlueC using a Varian Cary Eclipse spectrophotometer (Varian, Mulgrave, Victoria, Australia).
Real-time kinetic, dose-response, and cell titration BRET assays
HEK293 cells were seeded in 6-well plates at a density of 630,000 cells per well. Except for BRET 1 cell titration assays, cells were harvested 24 h after transfection in HEPES-buffered phenol red-free Complete Medium containing 5% FCS and added to a poly-L-lysine-coated white 96-well plate (Nunc) that was then incubated at 37 °C, 5% CO 2 . 48 h after transfection, for eBRET studies, the plate was incubated at 37 °C, 5% CO 2 for 2 h with 40 μM EnduRen (Promega) to ensure substrate equilibrium was reached. For BRET 1 (including the BRET 1 dose-response assays) and BRET 2 studies, medium in the plate was replaced with PBS containing 5 μM coelenterazine h or 10 μM DeepBlueC and assays carried out immediately. BRET measurements were taken at 37 °C using the VICTOR ™ Light plate reader with Wallac 1420 software (Perkin Elmer Life Sciences, Turku, Finland). BRET 1 cell titration assays were performed in suspension where cells were harvested 48 h after transfection in PBS containing 5 μM coelenterazine h, transferred to a white 96-well plate (Nunc), and diluted according to the dilution factor immediately prior to commencing the assay. Except for the BRET 1 doseresponse assays, cells were assayed before and after treatment with 1 μM TRH or vehicle (PBS) as shown. For BRET kinetic assays, the final pretreatment reading is presented at the zero time point (time of ligand/vehicle addition). The data for the BRET 1 dose-response and cell titration assays were collected ~30 min after treatment. Filtered light emissions were sequentially measured for 3 sec in each of the "donor wavelength window" (370-450 nm for luciferases with DeepBlueC or 400-475 nm for luciferases with coelenterazine h and EnduRen) and "acceptor wavelength window" (500-525 nm for GFP10 or 520-540 nm for Venus). The BRET signal was calculated by subtracting the ratio of emission through the acceptor wavelength window over emission through the donor wavelength window for a vehicle-treated cell sample from the same ratio for a 2nd aliquot of the same cells treated with agonist, as described previously. 2, 8 Note that in this calculation, the vehicle-treated cell sample represents the background, eliminating the requirement for measuring a "donoronly" control sample. 2, 8 Maximal ligand-induced BRET ratio data from the BRET dose-response assays (observed following treatment with 1 µM TRH) were compared by 1-way ANOVA followed by Bonferroni's multiple comparison test.
BRET Z′ ′-factor assay HEK293 cells were seeded in 6-well plates at a density of 630,000 cells per well. Twenty-four hours after transfection, cells were harvested in HEPES-buffered phenol red-free Complete Media containing 5% FCS and added to an entire poly-L-lysine-coated white 96-well plate (Nunc) that was then incubated at 37 °C, 5% CO 2 . Medium in the plate was replaced with PBS containing 5 μM coelenterazine h and cells were assayed immediately after treatment with 1 μM TRH (positive control; rows 3-6) or vehicle (PBS; negative control; rows 1, 2, 7, 8). BRET measurements were taken at 37 °C using the VICTOR ™ Light plate reader with Wallac 1420 software (Perkin Elmer). Filtered light emissions were sequentially measured for 2 sec in each of the donor wavelength window (400-475 nm) and the acceptor wavelength window (520-540 nm). The BRET data were expressed as fluorescence/luminescence, meaning emission through the acceptor wavelength window over emission through the donor wavelength window. These are not BRET ratios as normally defined because the background is not subtracted. Instead, the background (negative control) data are presented along with the treated (positive control) data so that the variance associated with each can be compared. To assess the potential suitability of the assay for high-throughput screening, the Z′ factor was calculated with respect to the mean and standard deviation (SD) of control data using the equation Z′ = 1 -[(3SD of positive control + 3SD of negative control)/|mean of positive control -mean of negative control|]. 19 
RESULTS
Functional validation of GPCR/luminophore fusion proteins
Total inositol phosphate assays, routinely used to evaluate ligand-induced G q/11 -mediated signaling from TRHR, showed that hRluc-, Rluc2-, and Rluc8-tagged receptor function was comparable with the previously characterized TRHR/Rluc fusion protein 8, 12 (Fig. 1) . It should also be noted that the demonstration of a ligand-induced receptor/β-arrestin interaction shown below also provides evidence for functionality in itself.
Spectral analysis of luminescent proteins
The emission spectra from HEK293 cells transfected with 1 of the 4 TRHR/luminophore fusion proteins were observed. The emission maximum in each case was found to be ~480 nm for coelenterazine h (Fig. 2A) . The emission maxima could not be established for DeepBlueC using Rluc or hRluc, but a peak for both Rluc2 and Rluc8 was observed at ~420 nm (Fig. 2B) . As EnduRen is converted to coelenterazine h in cells prior to oxidation by luciferases, this substrate exhibits identical spectral properties to coelenterazine h (data not shown). Luminescence intensities of different luciferase mutants were compared under the same conditions. Irrespective of the coelenterazine analogue used, Rluc8 always exhibited the highest intensity, followed by Rluc2. Using coelenterazine h, maximal luminescence intensity was similar for TRHR/Rluc and TRHR/hRluc constructs, but increased ~2.5-fold for TRHR/Rluc2 and ~6-fold for TRHR/Rluc8 ( Fig. 2A) . Luminescence from oxidation of DeepBlueC by Rluc and hRluc was undetectable under these conditions. In contrast, luminescence was detected using the Rluc2 and Rluc8 constructs, with TRHR/Rluc8 exhibiting ~2.5-fold higher intensity than TRHR/ Rluc2 (Fig. 2B) .
Coelenterazine h is used for BRET 1 or, in its protected form, for eBRET, and DeepBlueC is used for BRET 2 . For BRET 1 , upon treatment with 1 µM TRH, HEK293 cells transfected with β-arrestin 2/Venus and 1 of the 4 TRHR/luminophore constructs displayed a 2nd peak or shoulder at ~530 nm in addition to that at 480 nm (Fig. 2C) . The appearance of the 2nd peak demonstrated a spectral shift resulting from resonance energy transfer, indicating that specific ligand-induced receptor/β-arrestin interactions had occurred. This was clearly more evident with Rluc2 and Rluc8 than with Rluc and hRluc. For BRET 2 , upon treatment with 1 µM TRH, cells transfected with β-arrestin 2/GFP10 and TRHR/Rluc2 or TRHR/Rluc8 displayed a 2nd peak at ~510 nm in addition to that at ~420 nm (Fig. 2D) . Furthermore, the peak with TRHR/Rluc8 was more obvious. A spectral shift was undetectable with TRHR/Rluc and TRHR/hRluc due to the lack of luminescence (as shown in Fig. 2B ).
Comparison of TRHR/luminophore fusion proteins in realtime kinetic BRET 1 , BRET 2 , and eBRET assays
BRET signals were detected from cells cotransfected with different TRHR/luminophore and β-arrestin 2/fluorophore combinations using coelenterazine h (BRET 1 ), DeepBlueC (BRET 2 ), or EnduRen (eBRET). Measurements were taken before and after addition of 1 µM TRH or vehicle (PBS). Rluc2 and Rluc8 resulted in higher luminescence intensity ( Fig. 3) and higher BRET signals ( Fig. 4) than Rluc or hRluc, regardless of the substrate used. Indeed, with a standard luminometer it is not possible to detect a BRET 2 signal for more than a few seconds with currently used luminophores (Rluc and hRluc) due to the low luminescence intensity resulting from DeepBlueC oxidation (Fig. 3B) . Consequently, the greater and more sustained luminescence from Rluc2 and Rluc8 now enables BRET 2 signals to be measured for at least 1 h (Fig. 4B) , thereby making the BRET 2 system substantially more amenable to monitoring protein-protein interactions. 
BRET dose-response assays
TRH titration BRET assays were performed to demonstrate the dose dependency of the response (Fig. 5) . Ligand-induced BRET 1 signals from HEK293 cells transfected with 1 of the 4 TRHR/luminophore fusion proteins and β-arrestin 2/Venus were detected. Measurements were taken ~30 min after adding various concentrations of TRH or vehicle (PBS). The maximal ligand-induced BRET ratio (observed following treatment with 1 µM TRH) was shown to differ significantly depending on the luminophore (TRHR/Rluc8 > TRHR/Rluc2 > TRHR/hRluc > TRHR/Rluc), without the potency of the response being affected (Fig. 5) . The EC 50 values obtained from 3 independent experiments (±SEM) were 4.6 ± 1.1 nM (TRHR/Rluc8), 4.8 ± 1.7 nM (TRHR/Rluc2), 4.9 ± 1.9 nM (TRHR/hRluc), and 4.0 ± 1.8 nM (TRHR/Rluc).
BRET cell titration assays
Cells were cotransfected with the different TRHR/luminophores and β-arrestin 2/Venus. BRET 1 signals were detected from these cells at various levels of dilution to demonstrate dependency on cell number (Fig. 6) . Measurements were taken ~30 min after addition of 1 µM TRH or vehicle (PBS). TRHR/Rluc8 (Fig. 6A) showed very consistent BRET signals at 1:1, 1:2, and 1:4 cell dilution ratios, thereafter decreasing gradually with decreasing cell number (increasing cell dilution). Similar data were obtained for TRHR/Rluc2 (Fig. 6B) . For TRHR/hRluc ( Fig. 6C) and GFP10 (B, D) and TRHR tagged with 1 of various luciferase constructs. Emission spectra were recorded immediately after substrate addition. In untreated cells, an emission maximum of ~480 nm or ~420 nm corresponds to luciferase oxidizing coelenterazine h (A) or DeepBlueC (B), respectively. In treated cells, an additional emission peak appears at 530 nm (C) or ~510 nm (D) that corresponds to emission from Venus or GFP10, respectively, thereby demonstrating BRET due to TRHR/βarrestin 2 interactions. Data are representative of at least 3 independent experiments. Note that EnduRen has identical spectral properties to coelenterazine h (data not shown).
TRHR/Rluc (Fig. 6D) , consistent data were only detected at the 1:1 and 1:2 ratios.
BRET Z′ ′-factor assays
To demonstrate the advantages of using Rluc2 and Rluc8 luminophores and to assess their potential suitability for BRET high-throughput screening assays, we have performed BRET Z′-factor assays. Z′ values for the different TRHR/luminophore fusion proteins were generated for BRET 1 assays detecting TRH-induced interaction with β-arrestin 2/Venus over time (Fig. 7) . Rluc8 constructs exhibited very consistent Z′ values of >0.6 in all independent experiments at all time points except 10 min, when the 3 results were 0.59, 0.59, and 0.67. Similar results were generated for Rluc2 constructs, although the Z′ values were less consistent and the mean generally slightly lower. The mean Z′ factor for hRluc constructs did not exceed 0.6 at any time point, and for Rluc constructs, only exceeded 0.6 at the 20 and 30 min time points (Fig. 7) . The superior BRET Z′-factor assay performance of Rluc8 and Rluc2 compared with hRluc and Rluc becomes increasingly apparent over time, as illustrated at the 60-min time point (Fig. 8) .
DISCUSSION
We have used dynamic TRHR/β-arrestin interactions to demonstrate the advantages of Rluc2, and more particularly Rluc8, for BRET assessment of physiologically important protein-protein GFP10 (B) . Luciferase substrates were added immediately prior to real-time measurements at 37 °C except for EnduRen that had been preincubated for 2 h. Luminescence was measured before and after addition of TRH or vehicle as these data were generated as part of BRET assays shown in Figure. 4 . We have found that the luminescence threshold for producing meaningful BRET data with the VICTOR ™ Light luminometer is ~10,000 cps and this is shown as a solid horizontal line. Data are representative of at least 3 independent experiments. Note the inset in (A) shows the data for coelenterazine h on a smaller scale. interactions in real time. It is becoming increasingly clear that GPCR/β-arrestin interactions are not only important for G proteinmediated signal desensitization and receptor internalization, but also for establishing a secondary signaling platform for agonistactivated yet G protein-independent signaling for extended time periods. 15, 16, 18 Consequently, there is significant utility in being able to monitor such interactions for these extended periods in real time with BRET. 8, 17 Furthermore, the potential for utilizing the interaction with β-arrestin as a BRET screening tool for GPCR agonists or antagonists has been described previously. 8, 9, 20 Our results demonstrate that novel luminophores recently developed by the Gambhir laboratory 10, 11 are likely to substantially improve the effectiveness of such assays for high-throughput screening. In this model system, codon humanization of Rluc to generate hRluc appears to result in little improvement in luminescence intensity or BRET signal. In contrast, with the use of Rluc2 or Rluc8 (that contain mutations in addition to codon humanization), it is not only possible to increase BRET signal magnitude but also to stabilize signals, allowing detection for a considerably longer time period and with fewer cells. Such improvements will be especially important for detecting protein-protein interactions that are weak, but critical for function. The use of high protein expression levels to produce BRET signals has been criticized due to the risk of detecting random interactions between molecules rather than specific protein-protein interactions. This is particularly important when interpreting data for constitutive interactions. 21
FIG. 4.
Detection of protein-protein interactions by real-time BRET 1 (A), BRET 2 (B), and eBRET (C) assays. Kinetic data comparing different thyrotropin-releasing hormone receptor (TRHR)/luminophore fusion proteins using TRH-induced interaction with β-arrestin 2/Venus (BRET 1 and eBRET) or β-arrestin 2/GFP10 (BRET 2 ). Transiently cotransfected HEK293 cells were assayed before and after treatment with TRH or vehicle. The luciferase substrate coelenterazine h for BRET 1 (A) or DeepBlueC for BRET 2 (B) was added immediately prior to real-time measurements at 37 °C. For eBRET studies (C), cells were preincubated with EnduRen for 2 h prior to BRET detection. The ligand-induced BRET ratios are calculated as described in Materials and Methods. Data shown are mean ± SEM of 3 independent experiments (A, B) or representative of 3 independent experiments (C). BRET 1 , BRET 2 , and eBRET, all 3 generations of bioluminescence resonance energy transfer (BRET).
FIG. 5.
Thyrotropin-releasing hormone (TRH) dose-response curves comparing TRH-induced interactions of different TRH receptor (TRHR)/luminophore fusion proteins with β-arrestin2/Venus using BRET 1 assays. The luciferase substrate coelenterazine h was added to transiently cotransfected HEK293 cells immediately prior to commencing the assay at 37 °C. Measurements were taken ~30 min after treatment with various concentrations of TRH or vehicle. The ligandinduced BRET ratios are calculated as described in Materials and Methods. Data shown are mean ± SEM of 3 independent experiments. BRET 1 , 1st generation of bioluminescence resonance energy transfer (BRET).
Rluc2 and Rluc8 greatly improve BRET signal sensitivity, especially for BRET 2 , and so there is now more scope for detection of transient and/or weak interactions with proteins expressed at physiologically relevant levels.
Different TRHR/luminophore fusion proteins were tested in BRET assays with 3 luciferase substrates (coelenterazine h, DeepBlueC, and EnduRen), representing the 3 generations of BRET that have come to be known as BRET 1 , BRET 2 , and eBRET, respectively. It was possible to show that in all cases luminescence and BRET signal were increased, stabilized, and sustained with Rluc2-and Rluc8-tagged fusion proteins when compared with Rluc-or hRluc-tagged proteins. This was demonstrated using both scanning spectrophotometry and analysis by sequentially filtered emission detection with a luminometer.
It is important to note that although in the case of BRET 1 (using coelenterazine h) and eBRET (using EnduRen), Rluc2 and Rluc8 do result in marked improvements to the assay, in the case of BRET 2 (using DeepBlueC) these novel luminophores increase luminescence intensity, and consequently assay sensitivity, by more than 2 orders of magnitude. Using standard BRET instrumentation, it was not previously possible to detect a BRET 2 signal without injection of DeepBlueC into individual wells prior to measurement because the signal lasted only a few seconds before dropping below the limits of detection. 9 Moreover, the lack of sensitivity would inevitably lead to a tendency for high protein expression levels to be used to detect a BRET 2 signal. At the very least, a large number of cells would be required. 9 Using Rluc2 or Rluc8 we have detected BRET 2 without requiring highly specialized instrumentation (such as a modified Topcount apparatus 22 ) and using the same luminophore cDNA concentration and number of cells as used for BRET 1 or eBRET. Furthermore, we were able to detect ligand-induced GPCR/β-arrestin interactions for more than 1 h with a very stable signal and negligible background noise. These developments open up new possibilities for application of the BRET 2 assay to real-time BRET kinetic studies over this time frame without signal intensity or decay being a limiting factor.
With the use of Rluc2 and Rluc8, the benefits of the BRET 2 system with respect to low background noise from greatly superior donor and acceptor spectral separation 1,2 (Fig. 2) are now likely to outweigh the disadvantages of poor signal intensity and duration. Furthermore, the improvements to BRET 2 mean that, for the 1st time, BRET 1 /BRET 2 multiplexing 23 can be carried out over long time periods, for example, enabling an Rluc8-tagged protein to be monitored interacting with Venusand GFP10-tagged proteins in parallel cell populations for more than 1 h rather than for seconds. 23 In addition to illustrating BRET signal dose dependency, and therefore specificity, the BRET dose-response assays support the conclusions from the BRET kinetic assays by demonstrating significant increases in maximal ligand-induced BRET ratios when utilizing the novel luminophores. Importantly, these increases occur without affecting response potency. This implies that altering the luminophore does not influence the potency of the response being detected, which in this case is dependent upon a number of cellular events including agonist binding, receptor phosphorylation, and β-arrestin binding.
The cell number used for assays with Rluc and hRluc had previously been set at a level that gave consistent results without the need for excessive numbers of cells. Therefore, it is not surprising that more than a halving of this number resulted in inconsistent data (Fig. 6) . However, the cell titration assays clearly illustrate the increased sensitivity achieved when using Rluc2 or Rluc8 compared with Rluc or hRluc, as strong and consistent ligand-induced BRET ratios were observed following dilution to levels at which the latter luminophores were no longer reliable. Furthermore, beyond a threshold level, the ligand-induced BRET ratio became highly dependent upon cell number as would be expected for a specific interaction.
The Z′ factor provides a useful tool for evaluating and comparing the quality of assays and can be utilized in assay optimization and validation. 19 This is because the coefficient is reflective of both the assay signal dynamic range and the data variation associated with the signal measurements. 19 The ability to identify active ligands from large chemical libraries accurately and rapidly is the ultimate goal in the development of high-throughput screening assays. Furthermore, as we increasingly appreciate the complexities of cellular signaling mechanisms, the acknowledged need to screen for compounds using ever more physiologically relevant systems is driving research into cell-based assay technologies. The data obtained from our BRET Z′-factor assays have clearly demonstrated the potential advantages of using Rluc2, and more particularly Rluc8, for BRET high-throughput screening assays with live cells. The improvements to the BRET 2 system are obvious from the luminescence data generated using the scanning spectrophotometer ( Fig. 2) and luminometer ( Fig. 3) . However, it is the Z′-factor data that most clearly illustrates the utility of using Rluc2 or Rluc8 with BRET 1 (Figs. 7 and 8) and similar improvements are observed with eBRET (data not shown). Rluc8 enables Z′factor data in excess of 0.6 to be reproduced consistently, both over time and on different days. This consistency of quality data acquisition is of particular value in the high-throughput screening environment.
In conclusion, we have demonstrated substantial advantages of using the Rluc2 and Rluc8 luminophores for BRET, further improving the sensitivity, and therefore the potential, of this live cell assay technology, which has exciting implications for drug discovery and our understanding of cellular biology.
FIG. 7.
Comparison of mean Z′ values for different thyrotropinreleasing hormone receptor (TRHR)/luminophore fusion proteins in the BRET 1 assay detecting TRH-induced interaction with β-arrestin 2/Venus over time. Transiently cotransfected HEK293 cells were treated with TRH (positive control) or vehicle (negative control) and luciferase substrate coelenterazine h that were both added immediately prior to real-time measurements at 37 °C. Z′ values are calculated as described in Materials and Methods. A horizontal line is shown for a Z′ factor of 0.6 as an indication of high assay performance. Data shown are mean ± SEM of 3 independent experiments. BRET 1 , 1st generation of bioluminescence resonance energy transfer (BRET). 
